Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Befort, Katia ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

cannabinoid; G protein coupled receptors; Genetically modified mice; Opioid; Reward

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CRE RECOMBINASE; DELTA OPIATE RECEPTOR; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; OPIATE;

ADDICTION; ANIMAL BEHAVIOR; BRAIN REGION; DOPAMINERGIC TRANSMISSION; EPIGENETICS; EXON; GENE DELETION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC CODE; GENETIC VARIABILITY; MOLECULAR INTERACTION; NEUROMODULATION; NEUROTRANSMITTER UPTAKE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; REWARD;

EID: 84926479312     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00006     Document Type: Review

References (189)

1. Aaltonen, N., Riera Ribas, C., Lehtonen, M., Savinainen, J. R., and Laitinen, J. T. (2014). Brain regional cannabinoid CB(1) receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice. Eur. J. Pharm. Sci. 51, 87-95. doi: 10.1016/j.ejps.2013.08.035
2. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J.,et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10, 870-879. doi: 10.1038/nn1916
3. Ahn, K., Mckinney, M. K., and Cravatt, B. F. (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108, 1687-1707. doi: 10.1021/cr0782067
4. Ansonoff, M. A., Zhang, J., Czyzyk, T., Rothman, R. B., Stewart, J., Xu, H.,et al. (2006). Antinociceptive and hypothermic effects of salvinorin a are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J. Pharmacol. Exp. Ther. 318, 641-648. doi: 10.1124/jpet.106.101998
5. Belin, D., and Deroche-Gamonet, V. (2012). Responses to novelty and vulnerability to cocaine addiction: contribution of a multi-symptomatic animal model. Cold Spring Harb. Perspect. Med. 2:a011940. doi: 10.1101/cshperspect.a011940.
6. Bellocchio, L., Lafenetre, P., Cannich, A., Cota, D., Puente, N., Grandes, P.,et al. (2010). Bimodal control of stimulated food intake by the endocannabinoid system. Nat. Neurosci. 13, 281-283. doi: 10.1038/nn.2494
7. Bellocchio, L., Soria-Gomez, E., Quarta, C., Metna-Laurent, M., Cardinal, P., Binder, E.,et al. (2013). Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc. Natl. Acad. Sci. U.S.A. 110, 4786-4791. doi: 10.1073/pnas.1218573110
8. Berrendero, F., Mendizabal, V., Murtra, P., Kieffer, B. L., and Maldonado, R. (2003). Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta-, and kappa-opioid receptor knockout mice. Eur. J. Neurosci. 18, 2197-2202. doi: 10.1046/j.1460-9568.2003.02951.x
9. Bodnar, R. J. (2014). Endogenous opiates and behavior: 2013. Peptides 62C, 67-136. doi: 10.1016/j.peptides.2014.09.013
10. Brady, L. S., Herkenham, M., Rothman, R. B., Partilla, J. S., Konig, M., Zimmer, A. M.,et al. (1999). Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. Brain Res. Mol. Brain Res. 68, 193-197. doi: 10.1016/S0169-328X(99)00090-X
11. Buckley, N. E., Mccoy, K. L., Mezey, E., Bonner, T., Zimmer, A., Felder, C. C.,et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396, 141-149. doi: 10.1016/S0014-2999(00)00211-9
12. Bushlin, I., Gupta, A., Stockton, S. D. Jr., Miller, L. K., and Devi, L. A. (2012). Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS ONE 7:e49789. doi: 10.1371/journal.pone.0049789
13. Castane, A., Robledo, P., Matifas, A., Kieffer, B. L., and Maldonado, R. (2003). Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur. J. Neurosci. 17, 155-159. doi: 10.1046/j.1460-9568.2003.02409.x
14. Chanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P.,et al. (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 78, 996-1003. doi: 10.1124/mol.110.068304
15. Charbogne, P., Kieffer, B. L., and Befort, K. (2014). 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology 76(Pt B), 204-217. doi: 10.1016/j.neuropharm.2013.08.028
16. Chu Sin Chung, P., Keyworth, H. L., Martin-Garcia, E., Charbogne, P., Darcq, E., Bailey, A.,et al. (2014). A novel anxiogenic role for the delta opioid receptor expressed in GABAergic forebrain neurons. Biol. Psychiatry doi: 10.1016/j.biopsych.2014.07.033 [Epub ahead of print].
17. Clarke, S., Czyzyk, T., Ansonoff, M., Nitsche, J. F., Hsu, M. S., Nilsson, L.,et al. (2002). Autoradiography of opioid and ORL1 ligands in opioid receptor triple knockout mice. Eur. J. Neurosci. 16, 1705-1712. doi: 10.1046/j.1460-9568.2002.02239.x
18. Clarke, S., Zimmer, A., Zimmer, A. M., Hill, R. G., and Kitchen, I. (2003). Region selective up-regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice. Neuroscience 122, 479-489. doi: 10.1016/j.neuroscience.2003.07.011
19. Contet, C., Kieffer, B. L., and Befort, K. (2004). Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370-378. doi: 10.1016/j.conb.2004.05.005
20. Cossu, G., Ledent, C., Fattore, L., Imperato, A., Bohme, G. A., Parmentier, M.,et al. (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118, 61-65. doi: 10.1016/S0166-4328(00)00311-9
21. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R.,et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98, 9371-9376. doi: 10.1073/pnas.161191698
22. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87. doi: 10.1038/384083a0
23. Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., and Lichtman, A. H. (2004). Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. U.S.A. 101, 10821-10826. doi: 10.1073/pnas.0401292101
24. Cui, Y., Ostlund, S. B., James, A. S., Park, C. S., Ge, W., Roberts, K. W.,et al. (2014). Targeted expression of mu-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward. Nat. Neurosci. 17, 254-261. doi: 10.1038/nn.3622
25. D'Addario, C., Di Francesco, A., Pucci, M., Finazzi Agro, A., and Maccarrone, M. (2013). Epigenetic mechanisms and endocannabinoid signalling. FEBS J. 280, 1905-1917. doi: 10.1111/febs.12125
26. De Luca, M. A., Valentini, V., Bimpisidis, Z., Cacciapaglia, F., Caboni, P., and Di Chiara, G. (2014). Endocannabinoid 2-arachidonoylglycerol self-administration by sprague-dawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens Shell. Front. Psychiatry 5:140. doi: 10.3389/fpsyt.2014.00140
27. De Petrocellis, L., and Di Marzo, V. (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 5, 103-121. doi: 10.1007/s11481-009-9177-z
28. Dhopeshwarkar, A., and Mackie, K. (2014). CB2 cannabinoid receptors as a therapeutic target-what does the future hold? Mol. Pharmacol. 86, 430-437. doi: 10.1124/mol.114.094649
29. Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M.,et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444. doi: 10.1046/j.1471-4159.2000.0752434.x
30. Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L.,et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99, 10819-10824. doi: 10.1073/pnas.152334899
31. Dubreucq, S., Kambire, S., Conforzi, M., Metna-Laurent, M., Cannich, A., Soria-Gomez, E.,et al. (2012a). Cannabinoid type 1 receptors located on single-minded 1-expressing neurons control emotional behaviors. Neuroscience 204, 230-244. doi: 10.1016/j.neuroscience.2011.08.049
32. Dubreucq, S., Matias, I., Cardinal, P., Haring, M., Lutz, B., Marsicano, G.,et al. (2012b). Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37, 1885-1900. doi: 10.1038/npp.2012.36
33. Erbs, E., Faget, L., Scherrer, G., Matifas, A., Filliol, D., Vonesch, J. L.,et al. (2014). A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct. Funct. doi: 10.1007/s00429-014-0717-9 [Epub ahead of print].
34. Evans, C. J., Keith, D. E. Jr., Morrison, H., Magendzo, K., and Edwards, R. H. (1992). Cloning of a delta opioid receptor by functional expression. Science 258, 1952-1955. doi: 10.1126/science.1335167
35. Everitt, B. J., and Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8, 1481-1489. doi: 10.1038/nn1579
36. Fattore, L., Cossu, G., Martellotta, C. M., and Fratta, W. (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl) 156, 410-416. doi: 10.1007/s002130100734
37. Fattore, L., Deiana, S., Spano, S. M., Cossu, G., Fadda, P., Scherma, M.,et al. (2005). Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol. Biochem. Behav. 81, 343-359. doi: 10.1016/j.pbb.2005.01.031
38. Fattore, L., and Fratta, W. (2011). Beyond THC: the new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 5:60. doi: 10.3389/fnbeh.2011.00060
39. Fernandez-Ruiz, J., Hernandez, M., and Ramos, J. A. (2010). Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e72-e91. doi: 10.1111/j.1755-5949.2010.00144.x
40. Ferre, S., Lluis, C., Justinova, Z., Quiroz, C., Orru, M., Navarro, G.,et al. (2010). Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br. J. Pharmacol. 160, 443-453. doi: 10.1111/j.1476-5381.2010.00723.x
41. Filizola, M., and Devi, L. A. (2014). Grand opening of structure-guided design for novel opioids. Trends Pharmacol. Sci. 34, 6-12. doi: 10.1016/j.tips.2012.10.002
42. Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W., Simonin, F.,et al. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25, 195-200. doi: 10.1038/76061
43. Flores, A., Maldonado, R., and Berrendero, F. (2014). The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward. Biol. Psychiatry 75, 499-507. doi: 10.1016/j.biopsych.2013.06.012
44. Fowler, C. D., and Kenny, P. J. (2012). Utility of genetically modified mice for understanding the neurobiology of substance use disorders. Hum. Genet. 131, 941-957. doi: 10.1007/s00439-011-1129-z
45. Fratta, W., and Fattore, L. (2013). Molecular mechanisms of cannabinoid addiction. Curr. Opin. Neurobiol. 23, 487-492. doi: 10.1016/j.conb.2013.02.002
46. Frazier, C. J. (2011). Key questions of endocannabinoid signalling in the CNS: which, where and when? J. Physiol. 589, 4807-4808. doi: 10.1113/jphysiol.2011.219493
47. Fujita, W., Gomes, I., and Devi, L. A. (2014). Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br. J. Pharmacol. 171, 4155-4176. doi: 10.1111/bph.12798
48. Gaffal, E., Cron, M., Glodde, N., Bald, T., Kuner, R., Zimmer, A.,et al. (2013). Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. J. Immunol. 190, 4929-4936. doi: 10.4049/jimmunol.1201777
49. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M.,et al. (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30, 2017-2024. doi: 10.1523/JNEUROSCI.5693-09.2010
50. Gardner, E. L. (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 81, 263-284. doi: 10.1016/j.pbb.2005.01.032
51. Gaveriaux-Ruff, C. (2013). Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants. Curr. Pharm. Des 19, 7373-7381. doi: 10.2174/138161281942140105163727
52. Gaveriaux-Ruff, C., Nozaki, C., Nadal, X., Hever, X. C., Weibel, R., Matifas, A.,et al. (2011). Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 152, 1238-1248. doi: 10.1016/j.pain.2010.12.031
53. Gerald, T. M., Howlett, A. C., Ward, G. R., Ho, C., and Franklin, S. O. (2008). Gene expression of opioid and dopamine systems in mouse striatum: effects of CB1 receptors, age and sex. Psychopharmacology (Berl.) 198, 497-508. doi: 10.1007/s00213-008-1141-1148
54. Gerald, T. M., Ward, G. R., Howlett, A. C., and Franklin, S. O. (2006). CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression. Brain Res. 1093, 20-24. doi: 10.1016/j.brainres.2006.03.088
55. Ghozland, S., Matthes, H. W., Simonin, F., Filliol, D., Kieffer, B. L., and Maldonado, R. (2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 22, 1146-1154.
56. Gong, J. P., Onaivi, E. S., Ishiguro, H., Liu, Q. R., Tagliaferro, P. A., Brusco, A.,et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10-23. doi: 10.1016/j.brainres.2005.11.035
57. Goody, R. J., Oakley, S. M., Filliol, D., Kieffer, B. L., and Kitchen, I. (2002). Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice. Brain Res. 945, 9-19. doi: 10.1016/S0006-8993(02)02452-6
58. Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E.,et al. (2011). Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718-779. doi: 10.1016/j.euroneuro.2011.08.008
59. Gutierrez-Cuesta, J., Burokas, A., Mancino, S., Kummer, S., Martin-Garcia, E., and Maldonado, R. (2014). Effects of genetic deletion of endogenous opioid system components on the reinstatement of cocaine-seeking behavior in mice. Neuropsychopharmacology. doi: 10.1038/npp.2014.149
60. Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F.,et al. (2012). Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148, 1039-1050. doi: 10.1016/j.cell.2012.01.037
61. Hough, L. B., Nalwalk, J. W., Chen, Y., Schuller, A., Zhu, Y., Zhang, J.,et al. (2000). Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res. 880, 102-108. doi: 10.1016/S0006-8993(00)02776-1
62. Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., and Damaj, M. I. (2013). The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology (Berl) 229, 591-601. doi: 10.1007/s00213-013-3117-6
63. Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R.,et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 96, 14136-14141. doi: 10.1073/pnas.96.24.14136
64. Jeong, W. I., Osei-Hyiaman, D., Park, O., Liu, J., Batkai, S., Mukhopadhyay, P.,et al. (2008). Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7, 227-235. doi: 10.1016/j.cmet.2007.12.007
65. Kieffer, B. L. (1995). Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol. Neurobiol. 15, 615-635. doi: 10.1007/BF02071128
66. Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., and Hirth, C. G. (1992). The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89, 12048-12052. doi: 10.1073/pnas.89.24.12048
67. Kieffer, B. L., and Gaveriaux-Ruff, C. (2002). Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285-306. doi: 10.1016/S0301-0082(02)00008-4
68. Kitchen, I., Slowe, S. J., Matthes, H. W., and Kieffer, B. (1997). Quantitative autoradiographic mapping of mu-, delta-, and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res. 778, 73-88. doi: 10.1016/S0006-8993(97)00988-8
69. Konig, M., Zimmer, A. M., Steiner, H., Holmes, P. V., Crawley, J. N., Brownstein, M. J.,et al. (1996). Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535-538. doi: 10.1038/383535a0
70. Koob, G. F. (2009). Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56(Suppl. 1), 18-31. doi: 10.1016/j.neuropharm.2008.07.043
71. Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238. doi: 10.1038/npp.2009.110
72. Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., and Butelman, E. R. (2012). Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J. Clin. Invest. 122, 3387-3393. doi: 10.1172/JCI60390
73. Le Merrer, J., Becker, J. A., Befort, K., and Kieffer, B. L. (2009). Reward processing by the opioid system in the brain. Physiol. Rev. 89, 1379-1412. doi: 10.1152/physrev.00005.2009
74. Le Naour, M., Akgun, E., Yekkirala, A., Lunzer, M. M., Powers, M. D., Kalyuzhny, A. E.,et al. (2013). Bivalent ligands that target mu opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. J. Med. Chem. 56, 5505-5513. doi: 10.1021/jm4005219
75. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F.,et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404. doi: 10.1126/science.283.5400.401
76. Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science 278, 45-47. doi: 10.1126/science.278.5335.45
77. Leung, D., Saghatelian, A., Simon, G. M., and Cravatt, B. F. (2006). Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720-4726. doi: 10.1021/bi060163l
78. Lichtman, A. H., Sheikh, S. M., Loh, H. H., and Martin, B. R. (2001). Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 298, 1007-1014.
79. Liu, J., Wang, L., Harvey-White, J., Huang, B. X., Kim, H. Y., Luquet, S.,et al. (2008). Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54, 1-7. doi: 10.1016/j.neuropharm.2007.05.020
80. Loacker, S., Sayyah, M., Wittmann, W., Herzog, H., and Schwarzer, C. (2007). Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130, 1017-1028. doi: 10.1093/brain/awl384
81. Loh, H. H., Liu, H. C., Cavalli, A., Yang, W., Chen, Y. F., and Wei, L. N. (1998). mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res. Mol. Brain Res. 54, 321-326. doi: 10.1016/S0169-328X(97)00353-7
82. Lopez-Moreno, J. A., Lopez-Jimenez, A., Gorriti, M. A., and De Fonseca, F. R. (2010). Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr. Drug Targets 11, 406-428. doi: 10.2174/138945010790980312
83. Lutz, P. E., Ayranci, G., Chu-Sin-Chung, P., Matifas, A., Koebel, P., Filliol, D.,et al. (2014). Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. Neuropsychopharmacology 39, 2694-2705. doi: 10.1038/npp.2014.126
84. Lutz, P. E., and Kieffer, B. L. (2013a). The multiple facets of opioid receptor function: implications for addiction. Curr. Opin. Neurobiol. 23, 473-479. doi: 10.1016/j.conb.2013.02.005
85. Lutz, P. E., and Kieffer, B. L. (2013b). Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 36, 195-206. doi: 10.1016/j.tins.2012.11.002
86. Maccarrone, M., Attina, M., Bari, M., Cartoni, A., Ledent, C., and Finazzi-Agro, A. (2001). Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J. Neurochem. 78, 339-348. doi: 10.1046/j.1471-4159.2001.00413.x
87. Maccarrone, M., Valverde, O., Barbaccia, M. L., Castane, A., Maldonado, R., Ledent, C.,et al. (2002). Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15, 1178-1186. doi: 10.1046/j.1460-9568.2002.01957.x
88. Mackie, K. (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 299-325.
89. Mackie, K. (2008). Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 20(Suppl. 1), 10-14. doi: 10.1111/j.1365-2826.2008.01671.x
90. Maldonado, R. (2002). Study of cannabinoid dependence in animals. Pharmacol. Ther. 95, 153-164. doi: 10.1016/S0163-7258(02)00254-1
91. Maldonado, R., Berrendero, F., Ozaita, A., and Robledo, P. (2011). Neurochemical basis of cannabis addiction. Neuroscience 181, 1-17. doi: 10.1016/j.neuroscience.2011.02.035
92. Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J.,et al. (1996). Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 273, 657-659. doi: 10.1126/science.273.5275.657
93. Maldonado, R., Robledo, P., and Berrendero, F. (2013). Endocannabinoid system and drug addiction: new insights from mutant mice approaches. Curr. Opin. Neurobiol. 23, 480-486. doi: 10.1016/j.conb.2013.02.004
94. Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29, 225-232. doi: 10.1016/j.tins.2006.01.008
95. Mansour, A., Fox, C. A., Akil, H., and Watson, S. J. (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22-29. doi: 10.1016/0166-2236(95)93946-U
96. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J. J., Ramos, J. A., and Fuentes, J. A. (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20, 287-294. doi: 10.1016/S0165-6147(99)01339-5
97. Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P.,et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492-497. doi: 10.1038/nm1561
98. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A.,et al. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88. doi: 10.1126/science.1088208
99. Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G.,et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534. doi: 10.1038/nature00839
100. Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., and Fratta, W. (1998). Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85, 327-330. doi: 10.1016/S0306-4522(98)00052-9
101. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., and Valverde, O. (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur. J. Neurosci. 12, 4038-4046. doi: 10.1046/j.1460-9568.2000.00287.x
102. Mascia, M. S., Obinu, M. C., Ledent, C., Parmentier, M., Bohme, G. A., Imperato, A.,et al. (1999). Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur. J. Pharmacol 383, R1-R2. doi: 10.1016/S0014-2999(99)00656-1
103. Massotte, D. (2014). In vivo opioid receptor heteromerization: where do we stand? Br. J. Pharmacol. 172, 420-434. doi: 10.1111/bph.12702
104. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. doi: 10.1038/346561a0
105. Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I.,et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823. doi: 10.1038/383819a0
106. Mendizabal, V., Zimmer, A., and Maldonado, R. (2006). Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology 31, 1957-1966. doi: 10.1038/sj.npp.1300957
107. Mestek, A., Hurley, J. H., Bye, L. S., Campbell, A. D., Chen, Y., Tian, M.,et al. (1995). The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci. 15, 2396-2406.
108. Mizoguchi, H., Watanabe, C., Osada, S., Yoshioka, M., Aoki, Y., Natsui, S.,et al. (2010). Lack of a rewarding effect and a locomotor-enhancing effect of the selective mu-opioid receptor agonist amidino-TAPA. Psychopharmacology (Berl) 212, 215-225. doi: 10.1007/s00213-010-1946-0
109. Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schutz, G.,et al. (2007). Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 5:e269. doi: 10.1371/journal.pbio.0050269
110. Monory, K., Massa, F., Egertova, M., Eder, M., Blaudzun, H., Westenbroek, R.,et al. (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51, 455-466. doi: 10.1016/j.neuron.2006.07.006
111. Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65. doi: 10.1038/365061a0
112. Nadal, X., La Porta, C., Andreea Bura, S., and Maldonado, R. (2013). Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur. J. Pharmacol. 716, 142-157. doi: 10.1016/j.ejphar.2013.01.077
113. Navarrete, F., Rodriguez-Arias, M., Martin-Garcia, E., Navarro, D., Garcia-Gutierrez, M. S., Aguilar, M. A.,et al. (2013). Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology 38, 2515-2524. doi: 10.1038/npp.2013.157
114. Nestler, E. J. (2014). Epigenetic mechanisms of drug addiction. Neuropharmacology 76 Pt B, 259-268. doi: 10.1016/j.neuropharm.2013.04.004
115. Niikura, K., Narita, M., Okutsu, D., Tsurukawa, Y., Nanjo, K., Kurahashi, K.,et al. (2008). Implication of endogenous beta-endorphin in the inhibition of the morphine-induced rewarding effect by the direct activation of spinal protein kinase C in mice. Neurosci. Lett. 433, 54-58. doi: 10.1016/j.neulet.2007.12.042
116. Nogueiras, R., Romero-Pico, A., Vazquez, M. J., Novelle, M. G., Lopez, M., and Dieguez, C. (2014). The opioid system and food intake: homeostatic and hedonic mechanisms. Obes. Facts 5, 196-207. doi: 10.1159/000338163
117. Oakley, S. M., Toth, G., Borsodi, A., Kieffer, B. L., and Kitchen, I. (2003). G-protein coupling of delta-opioid receptors in brains of mu-opioid receptor knockout mice. Eur. J. Pharmacol. 466, 91-98. doi: 10.1016/S0014-2999(03)01531-0
118. Ohno-Shosaku, T., and Kano, M. (2014). Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr. Opin. Neurobiol. 29C, 1-8. doi: 10.1016/j.conb.2014.03.017
119. Onaivi, E. S., Ishiguro, H., Gong, J. P., Patel, S., Perchuk, A., Meozzi, P. A.,et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 1074, 514-536. doi: 10.1196/annals.1369.052
120. Ortega-Alvaro, A., Ternianov, A., Aracil-Fernandez, A., Navarrete, F., Garcia-Gutierrez, M. S., and Manzanares, J. (2013). Role of cannabinoid CB receptor in the reinforcing actions of ethanol. Addict. Biol. doi: 10.1111/adb.12076
121. Pan, Y. X., Xu, J., Xu, M., Rossi, G. C., Matulonis, J. E., and Pasternak, G. W. (2009). Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc. Natl. Acad. Sci. U.S.A. 106, 4917-4922. doi: 10.1073/pnas.0811586106
122. Panagis, G., Mackey, B., and Vlachou, S. (2014). Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors: a step back into the future. Front. Psychiatry 5:92. doi: 10.3389/fpsyt.2014.00092
123. Panlilio, L. V., and Goldberg, S. R. (2007). Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102, 1863-1870. doi: 10.1111/j.1360-0443.2007.02011.x
124. Panlilio, L. V., Justinova, Z., and Goldberg, S. R. (2010). Animal models of cannabinoid reward. Br. J. Pharmacol. 160, 499-510. doi: 10.1111/j.1476-5381.2010.00775.x
125. Parolaro, D., Rubino, T., Vigano, D., Massi, P., Guidali, C., and Realini, N. (2010). Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr. Drug Targets 11, 393-405. doi: 10.2174/138945010790980367
126. Pattij, T., and De Vries, T. J. (2013). The role of impulsivity in relapse vulnerability. Curr. Opin. Neurobiol. 23, 700-705. doi: 10.1016/j.conb.2013.01.023
127. Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem 17, 1360-1381. doi: 10.2174/092986710790980050
128. Petrenko, A. B., Yamazaki, M., Sakimura, K., Kano, M., and Baba, H. (2014). Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol. Behav. Brain Res. 271, 51-58. doi: 10.1016/j.bbr.2014.05.063
129. Piomelli, D. (2014). More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 76 Pt B, 228-234. doi: 10.1016/j.neuropharm.2013.07.026
130. Pol, O., Murtra, P., Caracuel, L., Valverde, O., Puig, M. M., and Maldonado, R. (2006). Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Neuropharmacology 50, 123-132. doi: 10.1016/j.neuropharm.2005.11.002
131. Pradhan, A. A., Befort, K., Nozaki, C., Gaveriaux-Ruff, C., and Kieffer, B. L. (2011). The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol. Sci. 32, 581-590. doi: 10.1016/j.tips.2011.06.008
132. Pryce, G., Visintin, C., Ramagopalan, S. V., Al-Izki, S., De Faveri, L. E., Nuamah, R. A.,et al. (2014). Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J. 28, 117-130. doi: 10.1096/fj.13-239442
133. Ragnauth, A., Schuller, A., Morgan, M., Chan, J., Ogawa, S., Pintar, J.,et al. (2001). Female preproenkephalin-knockout mice display altered emotional responses. Proc. Natl. Acad. Sci. U.S.A. 98, 1958-1963. doi: 10.1073/pnas.041598498
134. Ramesh, D., Gamage, T. F., Vanuytsel, T., Owens, R. A., Abdullah, R. A., Niphakis, M. J.,et al. (2013). Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology 38, 1039-1049. doi: 10.1038/npp.2012.269
135. Ramesh, D., Ross, G. R., Schlosburg, J. E., Owens, R. A., Abdullah, R. A., Kinsey, S. G.,et al. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J. Pharmacol. Exp. Ther. 339, 173-185. doi: 10.1124/jpet.111.181370
136. Rice, O. V., Gordon, N., and Gifford, A. N. (2002). Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res. 945, 135-138. doi: 10.1016/S0006-8993(02)02890-1
137. Robbe, D., Kopf, M., Remaury, A., Bockaert, J., and Manzoni, O. J. (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 99, 8384-8388. doi: 10.1073/pnas.122149199
138. Robinson, T. E., and Berridge, K. C. (2008). Review. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3137-3146. doi: 10.1098/rstb.2008.0093
139. Robledo, P., Berrendero, F., Ozaita, A., and Maldonado, R. (2008). Advances in the field of cannabinoid-opioid cross-talk. Addict. Biol. 13, 213-224. doi: 10.1111/j.1369-1600.2008.00107.x
140. Roques, B. P., Fournie-Zaluski, M. C., and Wurm, M. (2012). Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat. Rev. Drug Discov. 11, 292-310. doi: 10.1038/nrd3673
141. Rubinstein, M., Mogil, J. S., Japon, M., Chan, E. C., Allen, R. G., and Low, M. J. (1996). Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 93, 3995-4000. doi: 10.1073/pnas.93.9.3995
142. Ruehle, S., Remmers, F., Romo-Parra, H., Massa, F., Wickert, M., Wortge, S.,et al. (2013). Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J. Neurosci. 33, 10264-10277. doi: 10.1523/JNEUROSCI.4171-12.2013
143. Sanchis-Segura, C., Cline, B. H., Marsicano, G., Lutz, B., and Spanagel, R. (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176, 223-232. doi: 10.1007/s00213-004-1877-1878
144. Sanchis-Segura, C., and Spanagel, R. (2006). Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict. Biol. 11, 2-38. doi: 10.1111/j.1369-1600.2006.00012.x
145. Saunders, B. T., and Robinson, T. E. (2013). Individual variation in resisting temptation: implications for addiction. Neurosci. Biobehav. Rev. 37, 1955-1975. doi: 10.1016/j.neubiorev.2013.02.008
146. Scavone, J. L., Sterling, R. C., and Van Bockstaele, E. J. (2013). Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248, 637-654. doi: 10.1016/j.neuroscience.2013.04.034
147. Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G.,et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113-1119. doi: 10.1038/nn.2616
148. Schuller, A. G., King, M. A., Zhang, J., Bolan, E., Pan, Y. X., Morgan, D. J.,et al. (1999). Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2, 151-156. doi: 10.1038/5706
149. Sharifi, N., Diehl, N., Yaswen, L., Brennan, M. B., and Hochgeschwender, U. (2001). Generation of dynorphin knockout mice. Brain Res. Mol. Brain Res. 86, 70-75. doi: 10.1016/S0169-328X(00)00264-3
150. Simonin, F., Befort, K., Gaveriaux-Ruff, C., Matthes, H., Nappey, V., Lannes, B.,et al. (1994). The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol. Pharmacol. 46, 1015-1021.
151. Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti, G.,et al. (1995). kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 92, 7006-7010. doi: 10.1073/pnas.92.15.7006
152. Simonin, F., Slowe, S., Becker, J. A., Matthes, H. W., Filliol, D., Chluba, J.,et al. (2001). Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur. J. Pharmacol. 414, 189-195. doi: 10.1016/S0014-2999(01)00822-6
153. Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A.,et al. (1998). Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17, 886-897. doi: 10.1093/emboj/17.4.886
154. Skoubis, P. D., Lam, H. A., Shoblock, J., Narayanan, S., and Maidment, N. T. (2005). Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur. J. Neurosci. 21, 1379-1384. doi: 10.1111/j.1460-9568.2005.03956.x
155. Slowe, S. J., Simonin, F., Kieffer, B., and Kitchen, I. (1999). Quantitative autoradiography of mu-delta- and kappa1 opioid receptors in kappa-opioid receptor knockout mice. Brain Res. 818, 335-345. doi: 10.1016/S0006-8993(98)01201-3
156. Solinas, M., Goldberg, S. R., and Piomelli, D. (2008). The endocannabinoid system in brain reward processes. Br. J. Pharmacol. 154, 369-383. doi: 10.1038/bjp.2008.130
157. Sora, I., Elmer, G., Funada, M., Pieper, J., Li, X. F., Hall, F. S.,et al. (2001). Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 25, 41-54. doi: 10.1016/S0893-133X(00)00252-9
158. Stein, C. (2013). Opioids, sensory systems and chronic pain. Eur. J. Pharmacol. 716, 179-187. doi: 10.1016/j.ejphar.2013.01.076
159. Steiner, H., Bonner, T. I., Zimmer, A. M., Kitai, S. T., and Zimmer, A. (1999). Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 5786-5790. doi: 10.1073/pnas.96.10.5786
160. Sun, X., Wang, H., Okabe, M., Mackie, K., Kingsley, P. J., Marnett, L. J.,et al. (2009). Genetic loss of faah compromises male fertility in mice. Biol. Reprod. 80, 235-242. doi: 10.1095/biolreprod.108.072736
161. Swendsen, J., and Le Moal, M. (2011). Individual vulnerability to addiction. Ann. N. Y. Acad. Sci. 1216, 73-85. doi: 10.1111/j.1749-6632.2010.05894.x
162. Szutorisz, H., Dinieri, J. A., Sweet, E., Egervari, G., Michaelides, M., Carter, J. M.,et al. (2014). Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology 39, 1315-1323. doi: 10.1038/npp.2013.352
163. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M.,et al. (2010). The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65, 320-327. doi: 10.1016/j.neuron.2010.01.021
164. Taschler, U., Radner, F. P., Heier, C., Schreiber, R., Schweiger, M., Schoiswohl, G.,et al. (2011). Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J. Biol. Chem. 286, 17467-17477. doi: 10.1074/jbc. M110.215434
165. Tebano, M. T., Martire, A., and Popoli, P. (2012). Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission. Brain Res. 1476, 108-118. doi: 10.1016/j.brainres.2012.04.051
166. Tian, M., Broxmeyer, H. E., Fan, Y., Lai, Z., Zhang, S., Aronica, S.,et al. (1997). Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J. Exp. Med. 185, 1517-1522. doi: 10.1084/jem.185.8.1517
167. Tomasiewicz, H. C., Jacobs, M. M., Wilkinson, M. B., Wilson, S. P., Nestler, E. J., and Hurd, Y. L. (2012). Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol. Psychiatry 72, 803-810. doi: 10.1016/j.biopsych.2012.04.026
168. Trigo, J. M., Martin-Garcia, E., Berrendero, F., Robledo, P., and Maldonado, R. (2010). The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 108, 183-194. doi: 10.1016/j.drugalcdep.2009.10.011
169. Tsuboi, K., Okamoto, Y., Ikematsu, N., Inoue, M., Shimizu, Y., Uyama, T.,et al. (2011). Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. Biochim. Biophys. Acta 1811, 565-577. doi: 10.1016/j.bbalip.2011.07.009
170. Tzschentke, T. M. (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12, 227-462. doi: 10.1111/j.1369-1600.2007.00070.x
171. Uchigashima, M., Yamazaki, M., Yamasaki, M., Tanimura, A., Sakimura, K., Kano, M.,et al. (2011). Molecular and morphological configuration for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-granule cell synapses in the dentate gyrus. J. Neurosci. 31, 7700-7714. doi: 10.1523/JNEUROSCI.5665-10.2011
172. Uriguen, L., Berrendero, F., Ledent, C., Maldonado, R., and Manzanares, J. (2005). Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice. Eur. J. Neurosci. 22, 2106-2110. doi: 10.1111/j.1460-9568.2005.04372.x
173. Valverde, O., Maldonado, R., Valjent, E., Zimmer, A. M., and Zimmer, A. (2000). Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J. Neurosci. 20, 9284-9289.
174. Valverde, O., and Torrens, M. (2012). CB1 receptor-deficient mice as a model for depression. Neuroscience 204, 193-206. doi: 10.1016/j.neuroscience.2011.09.031
175. Van't Veer, A., Bechtholt, A. J., Onvani, S., Potter, D., Wang, Y., Liu-Chen, L. Y.,et al. (2013). Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology 38, 1585-1597. doi: 10.1038/npp.2013.58
176. van Rijn, R. M., and Whistler, J. L. (2009). The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol. Psychiatry 66, 777-784. doi: 10.1016/j.biopsych.2009.05.019
177. Vigano, D., Rubino, T., and Parolaro, D. (2005). Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav. 81, 360-368. doi: 10.1016/j.pbb.2005.01.021
178. Vinod, K. Y., Sanguino, E., Yalamanchili, R., Manzanares, J., and Hungund, B. L. (2008). Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J. Neurochem. 104, 233-243. doi: 10.1111/j.1471-4159.2007.04956.x
179. Weibel, R., Reiss, D., Karchewski, L., Gardon, O., Matifas, A., Filliol, D.,et al. (2013). Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. PLoS ONE 8:e74706. doi: 10.1371/journal.pone.0074706
180. Wise, L. E., Shelton, C. C., Cravatt, B. F., Martin, B. R., and Lichtman, A. H. (2007). Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur. J. Pharmacol. 557, 44-48. doi: 10.1016/j.ejphar.2006.11.002
181. Wotherspoon, G., Fox, A., Mcintyre, P., Colley, S., Bevan, S., and Winter, J. (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135, 235-245. doi: 10.1016/j.neuroscience.2005.06.009
182. Xi, Z. X., Peng, X. Q., Li, X., Song, R., Zhang, H. Y., Liu, Q. R.,et al. (2011). Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat. Neurosci. 14, 1160-1166. doi: 10.1038/nn.2874
183. Yaswen, L., Diehl, N., Brennan, M. B., and Hochgeschwender, U. (1999). Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med. 5, 1066-1070. doi: 10.1038/12506
184. Yoshino, H., Miyamae, T., Hansen, G., Zambrowicz, B., Flynn, M., Pedicord, D.,et al. (2011). Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J. Physiol. 589, 4857-4884. doi: 10.1113/jphysiol.2011.212225
185. Zanettini, C., Panlilio, L. V., Alicki, M., Goldberg, S. R., Haller, J., and Yasar, S. (2011). Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front. Behav. Neurosci. 5:57. doi: 10.3389/fnbeh.2011.00057
186. Zhang, H. Y., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J.,et al. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1413210111
187. Zhu, Y., King, M. A., Schuller, A. G., Nitsche, J. F., Reidl, M., Elde, R. P.,et al. (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24, 243-252. doi: 10.1016/S0896-6273(00)80836-3
188. Zimmer, A., Valjent, E., Konig, M., Zimmer, A. M., Robledo, P., Hahn, H.,et al. (2001). Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J. Neurosci. 21, 9499-9505.
189. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner, T. I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 5780-5785. doi: 10.1073/pnas.96.10.5780